NCT06059495 (DEWI) is a Phase 2 clinical trial of Dostarlimab in Adenocarcinoma - GEJ, sponsored by GERCOR - Multidisciplinary Oncology Cooperative Group.

Who is sponsoring NCT06059495?

NCT06059495 is sponsored by GERCOR - Multidisciplinary Oncology Cooperative Group.

What drugs are being tested in NCT06059495?

Interventions in NCT06059495: Dostarlimab.

What condition does NCT06059495 study?

NCT06059495 studies Adenocarcinoma - GEJ, Gastric Adenocarcinoma.

Is NCT06059495 still recruiting?

NCT06059495 is currently recruiting now. Last updated 5 February 2024.

Last reviewed 2024-02-05 · How we verify

NCT06059495: DEWI

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Watch-and-Wait Approach With Dostarlimab in Localized dMMR/MSI-H Gastric Cancer: GERCOR Phase II Study

Recruiting now Phase 2 Last updated 5 February 2024

What this trial tests

Phase 2 trial testing Dostarlimab in Adenocarcinoma - GEJ in 59 participants. Currently enrolling.

Timeline

18 December 2023

Primary endpoint
1 September 2028

1 September 2028

Quick facts

Lead sponsor	GERCOR - Multidisciplinary Oncology Cooperative Group
Phase	Phase 2
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	59
Start date	18 December 2023
Primary completion	1 September 2028
Estimated completion	1 September 2028
Sites	2 locations across France

Drugs / interventions tested

Dostarlimab (DOSTARLIMAB) — full drug profile →

Conditions studied

Adenocarcinoma - GEJ — all drugs for Adenocarcinoma - GEJ →
Gastric Adenocarcinoma — all drugs for Gastric Adenocarcinoma →

Sponsor

GERCOR - Multidisciplinary Oncology Cooperative Group

Who can join

Adults 18 to 75, any sex, with Adenocarcinoma - GEJ or Gastric Adenocarcinoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This phase II study will evaluate dostarlimab with a watch-and-wait approach for patients with localized mismatch repair deficiency (dMMR)/microsatellite instability (MSI) gastric or oeso-gastric junction adenocarcinoma. The goal of the study is to determine whether the surgery could be avoided in patients with localized dMMR/MSI-H gastric/OGJ adenocarcinoma with complete response at endoscopy and biopsies free of tumoral cells after treatment with dostarlimab, with a watch-and-wait approaches.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Clinical status and future prospects of neoadjuvant immunotherapy for localized mismatch repair-deficient cancers: a review.
Li J. · · 2024 · cited 3× · PMID 38768473 · DOI 10.1097/js9.0000000000001680
Biology and evolving management of resectable dMMR/MSI-H cancers: current status and future perspectives.
Tanegashima T, Shiota M, Toyosaki K, Funakoshi K, et al · · 2025 · cited 1× · PMID 41196394 · DOI 10.1007/s00262-025-04223-9
Evolution of Therapeutics for Locally Advanced Upper Gastrointestinal Adenocarcinoma.
Li JJ, Rogers JE, Waters RE, Gan Q, et al · · 2025 · cited 1× · PMID 40282483 · DOI 10.3390/cancers17081307
Early- and advanced-stage MSI-H non-colorectal cancers: best management and challenges in 2025.
Fazio R, Ambrosini M, Raimondi A, Pircher CC, et al · · 2026 · PMID 41994006 · DOI 10.1016/j.esmogo.2025.100296

Verify or expand the search:

Other trials of Dostarlimab

Trials testing the same drug.

NCT07408063 — A Comprehensive Multiomic Biomarker Evaluation Across Two Single-arm Cohorts to Elucidate Mechanisms of Response and Res · Phase 2 · not yet recruiting
NCT07381777 — XELOX Plus DoSTARlimab Versus XELOX Alone as Consolidation Treatment After Standard Chemoradiation in pMMR/MSS or MSI-Lo · Phase 2 · not yet recruiting
NCT06405230 — Evaluation of Programmed Death Ligand 1 (PDL1) Response to Treatment in Extracellular Vesicles (EVs), Patient-derived Or · Phase 1, PHASE2 · recruiting
NCT07336147 — Dostarlimab, Cisplatin and Etoposide in Combination With Radiotherapy in Sandwich Sequence for Small Cell Neuroendocrine · Phase 2 · recruiting
NCT07108270 — A Study of Dostarlimab in Combination With Carboplatin-paclitaxel in Chinese Participants With Primary Advanced or Recur · Phase 2 · recruiting

Other GERCOR - Multidisciplinary Oncology Cooperative Group trials

Trials by the same sponsor.

NCT05787197 — ctDNA in CRC Patients Undergoing Curative-intent Surgery for Liver Metastases · recruiting
NCT04935853 — Prognostic and Predictive Markers of Response to Treatment in Patients With Bile Duct Cancer: ACABi PRONOBIL Study · recruiting
NCT04894123 — Cardiovascular Events From Trifluridine/Tipiracil +/- Oxaliplatin in Colorectal/Oesogastric Adenocarcinoma Patients · Phase 2 · terminated
NCT03704480 — Durvalumab + Tremelimumab ± Paclitaxel in Advanced BTC After Platinum Chemotherapy. · Phase 2 · active not recruiting
NCT03519295 — A Study of mDCF in Combination or Not With Atezolizumab in Advanced Squamous Cell Anal Carcinoma · Phase 2 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06059495 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by GERCOR - Multidisciplinary Oncology Cooperative Group
Last refreshed: 5 February 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06059495.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing